U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Direct-to-Consumer Television Advertisements: FDAAA DTC Television Ad Pre-Dissemination Review Program
  1. Regulatory Information

GUIDANCE DOCUMENT

Direct-to-Consumer Television Advertisements: FDAAA DTC Television Ad Pre-Dissemination Review Program March 2012

Draft

Not for implementation. Contains non-binding recommendations.

Direct-to-Consumer Television Advertisements: FDAAA DTC Television Ad Pre-Dissemination Review Program

Docket Number:
FDA-2012-D-0022
Issued by:
Guidance Issuing Office
Office of Regulatory Policy
Center for Biologics Evaluation and Research

The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled “Direct-to-Consumer Television Advertisements—FDAAA DTC Television Ad Pre-Dissemination Review Program.” This draft guidance is intended to assist sponsors of human prescription drug products, including biological drug products, who are subject to the pre-dissemination review of television advertisements (TV ads) provision of the Federal Food, Drug, and Cosmetic Act (the FD&C Act). (The term “pre-dissemination review” is used throughout the guidance to refer to review under the FD&C Act, which is entitled “Prereview of Television Advertisements.”) The draft guidance describes which TV ads FDA intends to make subject to this provision, explains how FDA will notify sponsors that an ad is subject to review under this provision, and describes the general and center-specific procedures sponsors should follow to submit their TV ads to FDA for pre-dissemination review in compliance with the FD&C Act. These proposed TV ads will be subject to a 45-calendar day review clock by FDA.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2012-D-0022.